Advanced Accelerator Applications(AAAP)
Advanced Accelerator Applications (AAA or Adacap) is a France-based pharmaceutical group, specialized in the field of nuclear medicine.
The group operates in all three segments of nuclear medicine (PET, SPECT and therapy) to diagnose and treat serious conditions in the fields of oncology, neurology, cardiology, infectious and inflammatory diseases.
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name | Drug Name | Approved | Patent Expires | Indication |
|---|---|---|---|---|
| Lutathera | Lutetium (177lu) oxodotreotide, Lutetium lu 177 dotatate | 2017-09-26 | ||
| Lysakare | Arginine | 2019-07-25 | — | |
| Netspot | Gallium dotatate ga | 2016-06-01 | ||
| Somakit toc | Edotreotide | 2016-12-08 |
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Indication |
|---|---|---|---|---|---|
1
2
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use